enGene's Bladder Cancer Therapy Shows Mixed Efficacy in Updated Trial Data
Event summary
- enGene reported updated interim results from its Phase 2 LEGEND trial, showing a 54% complete response rate at any time and 43% at six months for detalimogene in high-risk NMIBC patients.
- The progression rate to muscle-invasive disease was low at 3.2%, with 55% of patients experiencing treatment-related adverse events, mostly mild.
- Recent patient data (post-October 2025) showed lower response rates (39% at any time, 32% at six months), prompting further analysis.
- enGene plans to share these data at the American Urological Association meeting on May 15, 2026, and engage with the FDA for a potential BLA filing in the second half of 2026.
The big picture
enGene's detalimogene represents a novel approach to non-viral gene therapy for high-risk bladder cancer, leveraging its DDX platform to address a significant unmet medical need. The updated trial data, while showing promising response rates and a favorable safety profile, highlight the challenges of achieving durable responses. The company's strategic focus on engaging with the FDA and sharing data with the medical community underscores its commitment to advancing the therapy through regulatory pathways.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the current data for a BLA filing, given the mixed durability outcomes and recent lower response rates.
- Clinical Efficacy
- How the ongoing analysis of recent patient data will impact the overall efficacy profile of detalimogene.
- Market Positioning
- The pace at which enGene can differentiate detalimogene in a competitive landscape for BCG-unresponsive NMIBC treatments.
Related topics